FDA Clears AI-Powered Prostate Volume Measurement for Handheld Ultrasound
Offering expedited calculation of prostate volume, Clarius Prostate AI is reportedly the first AI-enabled prostate measurement tool to garner FDA clearance for use with handheld ultrasound.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Clarius Prostate AI, an artificial intelligence (AI) application for handheld ultrasound that enables rapid calculation of prostate volume.
In contrast to manual processes with traditional ultrasound, clinicians can utilize the Clarius app to access Clarius Prostate AI, which highlights the prostate gland and facilitates caliper placement to measure prostate volume, according to Clarius, the developer of Clarius Prostate AI.
The newly FDA-cleared Clarius Prostate AI, which enables rapid calculation of prostate volume with handheld ultrasound, is currently available with Clarius handheld ultrasound scanners that allow customization for urology exams. (Image courtesy of Clarius Mobile Health.)
The company said Clarius Prostate AI, which is being showcased at the American Urological Association (AUA) conference April 26-29, also calculates prostate-specific antigen (PSA) density by combining the prostate volume measurement with the inputted patient’s PSA level.
"95% of clinicians we recently surveyed believe AI-powered measurements would save them time and allow them to see more patients. Manual ultrasound prostate volume measurements are repetitive and time-consuming, regardless of experience. With Clarius Prostate AI, what used to take several minutes now takes seconds, no matter your experience level,” noted Sarah Leverett, the vice president of marketing at Clarius Mobile Health.
Clarius noted that Clarius Prostate AI is currently available with Clarius handheld ultrasound scanners, including the C3 HD3 for transabdominal ultrasound and the EC7 HD3 for transrectal imaging, that offer customization for urology exams.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
